Telmisartan

Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD

Retrieved on: 
Wednesday, January 31, 2024
UUO, Kidney disease, CKD, AGN, Fibrosis, RSU, Patent, Chronic kidney disease, Telmisartan, Pharmaceutical industry

VANCOUVER, British Columbia, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has received a notice of intention to grant from the Chinese Patent Office for patent application No.

Key Points: 
  • VANCOUVER, British Columbia, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has received a notice of intention to grant from the Chinese Patent Office for patent application No.
  • The base claims of the patent will be valid through 2038, excluding any patent term adjustments or extensions, which may provide additional protection.
  • The Company was recently issued patents for Repirinast in chronic kidney disease (CKD) from Japan and has also filed corresponding patent applications in Canada, Europe and the United States.
  • “We are once again pleased to receive another notice of intent to grant a patent from the Chinese Patent Office,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals.

Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD

Retrieved on: 
Thursday, November 30, 2023
NAFLD, Risk, NASH, Fatty liver disease, AGN, Type, Inflammation, Standard of care, Patent, Insulin resistance, Laboratory, Obesity, Patient, Telmisartan, Steatosis, Fibrosis, UUO, CKD, Pharmaceutical industry

The invention claims treating lobular inflammation and nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH) and NASH-derived hepatocellular carcinoma, with Repirinast.

Key Points: 
  • The invention claims treating lobular inflammation and nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH) and NASH-derived hepatocellular carcinoma, with Repirinast.
  • The base claims of the patent will be valid through 2038, excluding any patent term adjustments or extensions which may provide additional protection.
  • The Company was recently issued patents for Repirinast in NASH from the U.S. and Japan, and has also filed corresponding patent applications in Canada and Europe.
  • “We are pleased to receive this notice of intent to grant from the Chinese Patent Office,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals.

Algernon Pharmaceuticals Receives Japanese Patent Notice of Allowance for Treatment of NASH with Repirinast

Retrieved on: 
Wednesday, November 8, 2023
Standard of care, Patent, Obesity, Laboratory, Fibrosis, Inflammation, CSE, Fatty liver disease, Type, Steatosis, NASH, Risk, UUO, Telmisartan, AGN, NAFLD, CKD, Insulin resistance, Patient, Pharmaceutical industry, Repirinast

VANCOUVER, British Columbia, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has received a Notice of Allowance from the Japanese Patent Office for patent application No.

Key Points: 
  • VANCOUVER, British Columbia, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical development company is pleased to announce that it has received a Notice of Allowance from the Japanese Patent Office for patent application No.
  • The invention claims treating nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH) and NASH-derived hepatocellular carcinoma, with Repirinast.
  • The base claims of the patent will be valid through 2038, excluding any patent term adjustments or extensions which may provide additional protection.
  • The Company was recently issued a patent from the US patent office for Repirinast in NASH and has also filed corresponding patent applications in Canada, Europe, and China.

Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH

Retrieved on: 
Wednesday, September 6, 2023
Telmisartan, Patent, Steatosis, Insulin resistance, Laboratory, Obesity, CSE, NASH, AGN, Inflammation, UUO, Fibrosis, Algernon, Standard of care, Patient, Risk, Fatty liver disease, Type, NAFLD, CKD, Pharmaceutical industry, Repirinast

11744808, for its lead chronic kidney Disease (CKD) program drug NP-251 (Repirinast), entitled “Compositions and Methods for Treating Non-Alcoholic Steatohepatitis.”

Key Points: 
  • 11744808, for its lead chronic kidney Disease (CKD) program drug NP-251 (Repirinast), entitled “Compositions and Methods for Treating Non-Alcoholic Steatohepatitis.”
    The invention claims treating non-alcohol fatty liver disease (NAFLD), including non-alcoholic steatohepatitis (NASH) and NASH-derived hepatocellular carcinoma, with Repirinast.
  • The base claims of the patent will be valid through 2039, excluding any patent term adjustments or extensions which may provide additional protection.
  • The Company has also filed corresponding patent applications in Canada, Europe, China and Japan.
  • “This is the first patent received from the USPTO by Algernon for one of its drugs being investigated under its innovative drug repurposing program and is further validation of our intellectual property strategy,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals.

George Medicines completes recruitment of first Phase III hypertension trial investigating novel single-pill triple combination candidate GMRx2

Retrieved on: 
Wednesday, July 12, 2023
Telmisartan, Diabetes, Disability, ICTU, Indapamide, Hypertension, Patient, Amlodipine, Death, Imperial College London, Safety, Pharmaceutical industry, Novel

George Medicines’ mission is to extend and improve the lives of the millions of people suffering from non-communicable cardiometabolic diseases – the world’s leading causes of death and disability, including hypertension and diabetes.

Key Points: 
  • George Medicines’ mission is to extend and improve the lives of the millions of people suffering from non-communicable cardiometabolic diseases – the world’s leading causes of death and disability, including hypertension and diabetes.
  • Globally, over a billion people worldwide have hypertension but fewer than one in five have the condition under control.
  • GMRx2 is formulated in novel, patent-protected low and ultra-low doses, to be a simple, go-to solution to reach targeted blood pressure control across different patient types.
  • Dr. Karl Roberts, Chief Operating Officer of George Medicines, said: “The progress of this Phase III programme is a huge testament to the dedication of the team and our partners working to bring GMRx2 to patients.

Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD

Retrieved on: 
Wednesday, May 31, 2023
Telmisartan, Patent, Asthma, CSE, Heart failure, AGN, Medicine, JPO, Fibrosis, Algernon, Diabetic nephropathy, CKD, Kidney disease, Pharmaceutical industry, Repirinast

The Company has also filed corresponding patent applications in the United States, Canada, Europe and China.

Key Points: 
  • The Company has also filed corresponding patent applications in the United States, Canada, Europe and China.
  • The invention claims the administration of Repirinast, either alone or in combination with telmisartan, for use in the prophylaxis or treatment of renal fibrosis or kidney disease.
  • “This is the first allowance notice received from the JPO by Algernon for one of the drugs being investigated under our innovative drug repurposing program and is further validation of our intellectual property strategy,” said Christopher J. Moreau, CEO of Algernon Pharmaceuticals.
  • “What is also noteworthy, is that Repirinast was originally developed and approved in the Japanese market for the treatment of asthma and so this notice of allowance is even more meaningful.”

Algernon Pharmaceuticals Announces Notice of Allowance for Method of Use U.S. Patent Application

Retrieved on: 
Monday, April 17, 2023
Telmisartan, Patent, Steatosis, Insulin resistance, Laboratory, Obesity, CSE, Heart failure, NASH, United States Patent and Trademark Office, AGN, Medicine, Inflammation, UUO, Fibrosis, Algernon, Standard of care, Patient, Risk, Fatty liver disease, Type, NAFLD, Diabetic nephropathy, CKD, Pharmaceutical industry, Repirinast

The Company has also filed corresponding patent applications in Canada, Europe, China and Japan.

Key Points: 
  • The Company has also filed corresponding patent applications in Canada, Europe, China and Japan.
  • The invention claims treating non-alcohol fatty liver disease (NAFLD), including non-alcoholic steatohepatitis (NASH) and NASH-derived hepatocellular carcinoma, with Repirinast.
  • Algernon’s intellectual property strategy for its repurposed drug program includes protecting its compounds by filing patent applications including method of use, dosing, and formulations, and for new composition of matter patents based on novel salt forms.
  • “This is the first allowance notice received from the USPTO by Algernon for one of the drugs being investigated under our innovative drug repurposing program and is further validation of our intellectual property strategy,” said Christopher J. Moreau, CEO of Algernon Pharmaceuticals.

Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study

Retrieved on: 
Monday, July 11, 2022
Idiopathic pulmonary fibrosis, Blood pressure, Swelling, Kidney, CSE, CKD, Inflammation, US, Engineering, CGMP, DMT, Stroke, Blood, Company, CAGR, AGN, Anemia, Time, Mitsubishi Tanabe Pharma, Kidney disease, Chronic kidney disease, GLOBE, Research, Patient, Fibrosis, Pharmaceutical industry, Repirinast, Telmisartan

VANCOUVER, British Columbia, July 11, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc.(the Company or Algernon) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage Canadian pharmaceutical development company, is pleased to provide an update on its chronic kidney disease (CKD) research program with NP-251 (Repirinast).

Key Points: 
  • VANCOUVER, British Columbia, July 11, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc.(the Company or Algernon) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a clinical stage Canadian pharmaceutical development company, is pleased to provide an update on its chronic kidney disease (CKD) research program with NP-251 (Repirinast).
  • In a pre-clinical animal model of kidney fibrosis, Repirinast reduced fibrosis by 50% with statistical significance.
  • Once completed, the Company plans to begin a small Phase 1 study in Q4, 2022, to determine the bioavailability of its Repirinast finished product.
  • Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.

Jacobson Pharma Announces FY2022 Annual Results

Retrieved on: 
Wednesday, June 29, 2022
Patient, Medication, Research, Marketing, COVID-19, Growth, Pramipexole, Company, Tax, JBM, Febuxostat, Guangdong-Hong Kong-Macau Greater Bay Area, Vaccination, Acceleration, Development, Department, Depreciation, EBITDA, Big White Duel, GMP, Acute promyelocytic leukemia, Idarubicin, Department of Health (Hong Kong), Fosun International, Fosun Pharma, Diabetes, Medical device, Conditional sentence, Greater, Dexmedetomidine, Health care, Public sector, Hospital, Board, PIC/S, HK, Analgesic, Sale, Amlodipine, The Group, University, Cardiovascular disease, Tablet, Immunity, Generic drug, Pharmaceutical industry, Vaccine, Valsartan, Group, Vaccine, Telmisartan, Brimonidine

HONG KONG, June 29, 2022 - (ACN Newswire) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of essential medicines, specialty drugs and branded healthcare products, today announced the annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2022 ("FY2022" or the "Reporting Period").

Key Points: 
  • HONG KONG, June 29, 2022 - (ACN Newswire) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of essential medicines, specialty drugs and branded healthcare products, today announced the annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2022 ("FY2022" or the "Reporting Period").
  • About Jacobson Pharma Corporation Limited (Stock Code: 2633)
    Jacobson Pharma is a leading pharmaceutical company in Hong Kong vertically integrated and engaged in the research, development, production, sale and distribution of essential medicines and specialty drugs.
  • Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017.
  • For more details about Jacobson Pharma, please visit the Group's website: http://www.jacobsonpharma.com
    Copyright 2022 ACN Newswire .

CymaBay Therapeutics Announces Presentations During The International Liver Congress™ 2022

Retrieved on: 
Wednesday, June 8, 2022
Woman, Conditional sentence, Itch, Congress, Alkaline phosphatase, University, NL, Seladelpar, Fibrosis, Carbon tetrachloride, EASL, European Association for the Study of the Liver, Liver cancer, Farnesoid X receptor, Hepatitis, Fatigue, Thyroid hormone receptor, Doctor of Philosophy, Peroxisome, Associate, Priority, Bile, Annual report, Security (finance), Disease, U.S. Securities and Exchange Commission, Inflammation, Cholestasis, Primary biliary cholangitis, ALP, Gene, CA, Telmisartan, Lipid metabolism, PBC, Therapy, Patient, Thyroid, THR, Risk, University of California, San Diego Performance-Based Skills Assessment, Food and Drug Administration, NASDAQ, European Medicines Agency, Twitter, Association, Erasmus MC, LinkedIn, FXR, Medical device, Pharmaceutical industry, Copper, Biostatistics, GLOBE, Liver

NEWARK, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that multiple seladelpar presentations will be delivered during The International Liver Congress 2022 of the European Association for the Study of Liver (EASL) which will be held in London, UK from June 22nd 26th.

Key Points: 
  • NEWARK, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that multiple seladelpar presentations will be delivered during The International Liver Congress 2022 of the European Association for the Study of Liver (EASL) which will be held in London, UK from June 22nd 26th.
  • Dr. Dennis Kim, Chief Medical Officer of CymaBay Therapeutics, commented, We are excited to have the opportunity to present once again this year at the International Liver Congress.
  • Presentations at The International Liver Congress 2022 include:
    Congress attendees can visit CymaBay throughout the meeting at booth 93.
  • A full list of presentations can be found on The International Liver Congress 2022 website.